References
- Pickar JH. Conflicts of interest in government-funded studies. Climacteric 2015;18:339–42
- Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized trial. JAMA 2002;288:321–33
- North American Menopause Society. The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2102;18:257–71
- Moyer VA; U.S. Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic diseases: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47–54
- Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in post-menopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999–2010. Obstet Gynecol 2012;120:595–603
- Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended post-stopping phases of the Women's Health Initiative randomized trials. JAMA 2013;310:1353–68
- Tatsioni A, Siontis GCM, Ioannides JPA. Partisan perspectives in the medical literature: a study of high frequency editorialists favoring hormone replacement therapy. J Gen Intern Med 2010;25:914–19
- Fugh-Berman AJ. The haunting of medical journals: how ghostwriting sold “HRT”. PLoS Med September 2010;7(9) e1000335
- de Villiers TJ, Pines A, Panay N, et al.; International Menopause Society. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013;16:316–37
- World Association of Medical Editors. Conflicts of interest in peer-reviewed medical journals. J Child Neurol 2009;24:1321–3
- Roth JA, Etzioni R, Waters TM, et al. Economic returns from the Women's Health Initiative estrogen plus progestin clinical trial. Ann Intern Med 2014;160:594–602
- Sarrel PM, Njike VY, Vinante V, Katz DL. The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women age 50 to 59 years. Am J Public Health 2013;103:1583–8
- Prentice RL, Manson JE, Anderson GL, et al. Women's Health Initiative view of estrogen avoidance and all-cause mortality. Am J Public Health 2013;103(12):e2
- Hernan MA, Alonso A, Logan R, et al. Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology 2008;19:766–79
- Rosenberg RN, Anderson ER. Editorial governance of the Journal of the American Medical Association. JAMA 1999;281: 2239–42
- Anderson GL, Kooperberg C, Geller N, Rossouw JE, Pettinger M, Prentice RL. Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clin Trials 2007;4:207–17
- Taleb NN. The Black Swan. The Impact of the Highly Improbable, 2nd edn. USA: Random House, 2007